Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Relmada Therapeutics (RLMD)
NASDAQ:RLMD
RESEARCH TOOLSreports
Relmada Therapeutics (RLMD) Stock Price & Analysis
281 Followers
RLMD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.42 - $7.22
Previous Close$4.16
Volume91.96K
Average Volume (3M)104.12K
Market Cap
$125.52M
Enterprise Value$29.20M
Total Cash (Recent Filing)$96.32M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Aug 06, 2024EPS Estimate
-$0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.13
Shares Outstanding30,174,202
10 Day Avg. Volume72,680
30 Day Avg. Volume104,122
Standard Deviation0.32
R-Squared0.00409
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.07
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.45
Forecast
1Y Price Target
$12.33Price Target Upside196.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Relmada Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial StabilityRelmada ended 1Q24 with $83.6M in cash, which should fully fund these two pivotal trials to completion.
Management OptimismManagement continues to show optimism about the upcoming RELIANCE II readout.
Trial Quality And AdjustmentsGood trial management and oversight are key factors in increasing the likelihood of positive results from RELIANCE II and Relight trials.
Bears Say
Analyst DowngradeAnalyst downgrades RLMD from Neutral to Sell and lowers the 12-month price target to $2 from $3 due to increased risk associated with the Ph3 RELIANCE II trial.
Prescription HesitationKey opinion leaders express hesitation to prescribe REL-1017, even if approved, due to lingering concerns over abuse potential.
Trial ExecutionPotential impact from the same trial execution missteps that led to the failure of the two prior Ph3 RELIANCE I and RELIANCE III trials is noted.
---
Ownership Overview
2.04% Insiders
9.26% Mutual Funds
8.88% Other Institutional Investors
79.82% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RLMD FAQ
What was Relmada Therapeutics’s price range in the past 12 months?
Relmada Therapeutics lowest stock price was $2.42 and its highest was $7.22 in the past 12 months.
What is Relmada Therapeutics’s market cap?
Currently, no data Available
When is Relmada Therapeutics’s upcoming earnings report date?
Relmada Therapeutics’s upcoming earnings report date is Aug 06, 2024 which is in 15 days.
How were Relmada Therapeutics’s earnings last quarter?
Relmada Therapeutics released its earnings results on May 08, 2024. The company reported -$0.72 earnings per share for the quarter, beating the consensus estimate of -$0.85 by $0.13.
Is Relmada Therapeutics overvalued?
According to Wall Street analysts Relmada Therapeutics’s price is currently Undervalued.
Does Relmada Therapeutics pay dividends?
Relmada Therapeutics does not currently pay dividends.
What is Relmada Therapeutics’s EPS estimate?
Relmada Therapeutics’s EPS estimate is -$0.83.
How many shares outstanding does Relmada Therapeutics have?
Relmada Therapeutics has 30,174,202 shares outstanding.
What happened to Relmada Therapeutics’s price movement after its last earnings report?
Relmada Therapeutics reported an EPS of -$0.72 in its last earnings report, beating expectations of -$0.85. Following the earnings report the stock price went down -0.783%.
Which hedge fund is a major shareholder of Relmada Therapeutics?
Among the largest hedge funds holding Relmada Therapeutics’s share is Fortitude Family Office, LLC. It holds Relmada Therapeutics’s shares valued at 2K.
---
Relmada Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.33 (196.39% Upside)
$12.33 (196.39% Upside)
Blogger Sentiment
Bullish
RLMD Sentiment 66%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
51.27%
12-Months-Change
Fundamentals
Return on Equity
-95.48%
Trailing 12-Months
Asset Growth
-37.74%
Trailing 12-Months
Company Description
Relmada Therapeutics
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases and other disorders. The company was founded on May 31, 2012 and is headquartered in New York, NY.
---
RLMD Earnings Call
Q1 2024
0:00 / 0:00
---
RLMD Stock 12 Month Forecast
Average Price Target
$12.33
▲(196.39% Upside)
Technical Analysis
Protagonist Therapeutics
―
Avadel Pharmaceuticals
―
Alnylam Pharma
―
Karyopharm Therapeutics
―
Best Analysts Covering RLMD
1 Year
1 Year Success Rate
9/16 ratings generated profit
1 Year Average Return
-1.72%
reiterated a buy rating 2 months ago
Copying Uy Ear's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of -1.72% per trade.
---